Dr Phillip Earle Williams, MD | |
7515 Greenville Ave, # 1000, Dallas, TX 75231-3831 | |
(214) 369-3333 | |
(214) 369-9933 |
Full Name | Dr Phillip Earle Williams |
---|---|
Gender | Male |
Speciality | Neurological Surgery |
Location | 7515 Greenville Ave, Dallas, Texas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306800750 | NPI | - | NPPES |
099333901 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | MDD2172 (Texas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Phillip Earle Williams, MD 7515 Greenville Ave, # 1000, Dallas, TX 75231-3831 Ph: (214) 369-3333 | Dr Phillip Earle Williams, MD 7515 Greenville Ave, # 1000, Dallas, TX 75231-3831 Ph: (214) 369-3333 |
News Archive
A two-day summit of the African Capacity Building Foundation (ACBF) in the Rwandan capital, Kigali, concluded on Wednesday with African leaders calling for stronger "efforts in building capacity that goes beyond achieving the Millennium Development Goals (MDGs) target of 2015," the New Times reports.
Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that it has signed agreements with four new European distributors in Germany, Spain, France and Turkey.
Many health care systems across the US have declined to participate in the Centers for Medicare and Medicaid Services' (CMMS) Accountable Care Organization (ACO) program, developed under the Patient Protection and Affordable Care Act (PPACA), to improve efficiency and quality of health care delivery.
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 ("miR-103/107") for the treatment of Non Alcoholic Steatohepatitis ("NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.
APCER Pharma Solutions, Inc. ("APCER") President and CEO Suneet Walia commented on the US Food and Drug Administration's (FDA) proposed rules to amend postmarket safety reporting regulations for three of its centers, to require manufacturers and other facilities subject to current reporting requirements to submit their reports electronically.
› Verified 8 days ago
Matthew Sun, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-9946 | |
Dr. Martin Lewis Lazar, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 7777 Forest Ln, Suite B420, Dallas, TX 75230 Phone: 972-566-6444 Fax: 972-566-6627 | |
Dr. Blake Arden Yarascavitch, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1935 Medical District Dr, Suite B-3200, Dallas, TX 75235 Phone: 214-456-6660 | |
Kalil G Abdullah, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5303 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2300 Fax: 214-648-2204 | |
James Ebot, DO Neurological Surgery Medicare: Medicare Enrolled Practice Location: 17218 Preston Rd Ste 2000, Dallas, TX 75252 Phone: 877-866-7123 | |
Dr. Charles Benjamin Newman, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1411 N Beckley Ave, Pav Iii Ste#152, Dallas, TX 75203 Phone: 214-948-2076 Fax: 214-948-9990 | |
Bruce Edward Mickey, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2300 Fax: 214-645-2301 |